12,132 followers
RT @FrontOncology: New research: Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review: Ba…
RT @FrontOncology: New research: Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review: Ba…
New research: Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review: Background/aim Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of… https://t.co/L